Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

被引:83
|
作者
Vaidya, Kaivan [1 ]
Tucker, Bradley [2 ,3 ]
Kurup, Rahul [1 ,2 ]
Khandkar, Chinmay [1 ]
Pandzic, Elvis [4 ]
Barraclough, Jennifer [1 ,2 ]
Machet, Joshua [3 ]
Misra, Ashish [2 ]
Kavurma, Mary [2 ]
Martinez, Gonzalo [5 ]
Rye, Kerry-Anne [3 ]
Cochran, Blake J. [3 ]
Patel, Sanjay [1 ,2 ,6 ]
机构
[1] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[2] Heart Res Inst, Sydney, NSW, Australia
[3] UNSW Sydney, Sch Med Sci, Sydney, NSW, Australia
[4] UNSW Sydney, Mark Wainwright Analyt Ctr, Biomed Imaging Facil, Sydney, NSW, Australia
[5] Pontificia Univ Catolica Chile, Div Cardiovasc Dis, Santiago, Chile
[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2021年 / 10卷 / 01期
关键词
acute coronary syndrome; inflammation; percutaneous coronary intervention; pharmacology; MYOCARDIAL-INFARCTION; PATHOPHYSIOLOGY; PREVENTION; THERAPY; UPDATE; SINUS;
D O I
10.1161/JAHA.120.018993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Release of neutrophil extracellular traps (NETs) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is associated with periprocedural myocardial infarction, as a result of microvascular obstruction via pro-inflammatory and prothrombotic pathways. Colchicine is a well-established anti-inflammatory agent with growing evidence to support use in patients with coronary disease. However, its effects on post-PCI NET formation in ACS have not been explored. METHODS AND RESULTS: Sixty patients (40 ACS; 20 stable angina pectoris) were prospectively recruited and allocated to colchicine or no treatment. Within 24 hours of treatment, serial coronary sinus blood samples were collected during PCI. Isolated neutrophils from 10 patients with ACS post-PCI and 4 healthy controls were treated in vitro with colchicine (25 nmol/L) and stimulated with either ionomycin (5 mu mol/L) or phorbol 12-myristate 13-acetate (50 nmol/L). Extracellular DNA was quantified using Sytox Green and fixed cells were stained with Hoechst 3342 and anti-alpha tubulin. Baseline characteristics were similar across both treatment and control arms. Patients with ACS had higher NET release versus patients with stable angina pectoris (P<0.001), which was reduced with colchicine treatment (area under the curve: 0.58 versus 4.29; P<0.001). In vitro, colchicine suppressed unstimulated (P<0.001), phorbol 12-myristate 13-acetate-induced (P=0.009) and ionomycin-induced (P=0.002) NET formation in neutrophils isolated from patients with ACS post-PCI, but not healthy controls. Tubulin organization was impaired in neutrophils from patients with ACS but was restored by colchicine treatment. CONCLUSIONS: Colchicine suppresses NET formation in patients with ACS post-PCI by restoring cytoskeletal dynamics. These findings warrant further investigation in randomized trials powered for clinical end points.
引用
收藏
页码:1 / 13
页数:22
相关论文
共 50 条
  • [1] Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention
    Aw, Kah Long
    Koh, Amanda
    Lee, Han Lin
    Kudzinskas, Aurimas
    De Palma, Rodney
    OPEN HEART, 2022, 9 (01):
  • [2] The Prognostic Value of a Derived Neutrophil-Lymphocyte Ratio in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Fan, Wenjun
    Zhang, Ying
    Gao, Xiuxin
    Liu, Yixiang
    Shi, Fei
    Liu, Jingyi
    Sun, Lixian
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [3] Efficacy of Cilostazol in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
    Hu, Taohong
    Ma, Huili
    Li, Huijun
    Ren, Jianghua
    AMERICAN JOURNAL OF THERAPEUTICS, 2013, 20 (02) : 151 - 153
  • [4] Patients' Perspectives With Acute Coronary Syndrome After Percutaneous Coronary Intervention
    Qin, Hong
    Mayer, Hanna
    Ozturk, Begum
    Eslam, Roza Badr
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (05): : 588 - 593
  • [5] Effects of remote ischemic preconditioning on contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome
    Zhou, Fazhan
    Song, Wei
    Wang, Zilong
    Yin, Luhua
    Yang, Shen
    Yang, Fubai
    Song, Zhaofeng
    Song, Yaguang
    Zhang, Huanyi
    Qiao, Fengjie
    Zhang, Zhimian
    MEDICINE, 2018, 97 (02)
  • [6] Clinical outcomes of patients undergoing percutaneous coronary intervention treated with colchicine
    Soria Jimenez, Cesar E.
    Sanz Sanchez, Jorge
    Brooke Levine, Molly
    Hayat, Fatima
    Chang, Jerway
    Garcia-Garcia, Hector M.
    REC-INTERVENTIONAL CARDIOLOGY, 2023, 5 (02): : 110 - 117
  • [7] State-of-the-Art Review: Percutaneous Coronary Intervention in Acute Coronary Syndrome
    Shah, Tayyab
    Fanaroff, Alexander C.
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2025, 27 (01)
  • [8] The early percutaneous coronary intervention in elderly patients with acute coronary syndrome
    Huang X.
    Cao X.
    Zhang G.
    Frontiers of Medicine in China, 2008, 2 (1): : 15 - 18
  • [9] Comorbidities and Percutaneous Coronary Intervention in Elderly Patients with Acute Coronary Syndrome
    Gilyarov, M. Yu
    Konstantinova, E., V
    Atabegashvili, M. R.
    Solntseva, T. D.
    Anichkov, D. A.
    Kostina, A. N.
    Polybin, R., V
    Udovichenko, A. E.
    Svet, A., V
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (02) : 221 - 227
  • [10] Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome
    Jia Xin-wei
    Fu Xiang-hua
    Zhang Jing
    Gu Xin-shun
    Fan Wei-ze
    Wu Wei-li
    Hao Guo-zhen
    Li Shi-qiang
    Jiang Yun-fa
    CHINESE MEDICAL JOURNAL, 2009, 122 (06) : 659 - 664